Christopher Pocock
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 30
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments 18
- Acute Myeloid Leukemia Research 12
- Hematopoietic Stem Cell Transplantation 8
-
- Lymphoma Diagnosis and Treatment 32
- Oncology top 5%
- Viral-associated cancers and disorders 8
- Rheumatology top 2%
- Eosinophilic Disorders and Syndromes 8
-
- CNS Lymphoma Diagnosis and Treatment 6
Christopher Pocock
63 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Genetics 1.1k
- Hematology 810
- Pathology and Forensic Medicine 1.2k
- Oncology 809
- Rheumatology 386
Countries citing papers authored by Christopher Pocock
This map shows the geographic impact of Christopher Pocock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Pocock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Pocock more than expected).
Fields of papers citing papers by Christopher Pocock
This network shows the impact of papers produced by Christopher Pocock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Pocock. The network helps show where Christopher Pocock may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Christopher Pocock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2021 | 31 | |
| 3 | 2019 | 116 | |
| 4 | 2018 | 10 | |
| 5 | 2018 | 20 | |
| 6 | 2017 | 81 | |
| 7 | 2016 | 6 | |
| 8 | 2014 | 24 | |
| 9 | 2013 | 22 | |
| 10 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesbreakdown → | 2013 | 357 |
| 11 | 2011 | 32 | |
| 12 | 2009 | 3 | |
| 13 | 2005 | 93 | |
| 14 | 2004 | 3 | |
| 15 | 2003 | 3 | |
| 16 | 2003 | 69 | |
| 17 | 2001 | 28 | |
| 18 | 2001 | 8 | |
| 19 | 2001 | 22 | |
| 20 | 1995 | 25 |
About Christopher Pocock
Christopher Pocock is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 64 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (30 papers), Chronic Myeloid Leukemia Treatments (18 papers), Acute Myeloid Leukemia Research (12 papers), Eosinophilic Disorders and Syndromes (8 papers), Viral-associated cancers and disorders (8 papers), Hematopoietic Stem Cell Transplantation (8 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). The work is most often cited by research in Genetics (1.1k citations), Hematology (810 citations) and Pathology and Forensic Medicine (1.2k citations). Christopher Pocock has collaborated with scholars based in United Kingdom, Australia and Spain. Frequent co-authors include David C. Linch, Kirit M. Ardeshna, Jane F. Apperley, David Cunningham, Andrew Jack, John Davies, John M. Goldman, Wendi Qian, John Radford and Peter Johnson. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, The Lancet Haematology and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.